Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC in ART-naive HIV-1-infected adolescents
NCT03682848Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started May 2019; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03682848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682848.